Seattle Genetics, Inc. (SGEN)’s President and CEO Clay Siegall Sold 18832 shares of the Company; Tortoise Capital Advisors Lifted Valero Energy Partners LP (VLP) Position

Clay Siegall, President and CEO of Seattle Genetics Inc Wa is the insider, we want to tell you about. Mr. Clay submitted a public form with the U.S. Security and Exchange Commission revealing a sale for 18,832 shares of the stock exchange listed company, the one he is an insider in. At the time of the trade, the average market share price of Seattle Genetics Inc Wa was $51.7, making the insider trade worth $973,873 USD. Clay Siegall owns 0.48% of the -company’s market cap or 687,146 shares.

Tortoise Capital Advisors Llc increased Valero Energy Partners Lp (VLP) stake by 0.41% reported in 2017Q3 SEC filing. Tortoise Capital Advisors Llc acquired 23,670 shares as Valero Energy Partners Lp (VLP)’s stock declined 7.37%. The Tortoise Capital Advisors Llc holds 5.73 million shares with $250.61 million value, up from 5.71M last quarter. Valero Energy Partners Lp now has $3.29B valuation. The stock decreased 0.24% or $0.11 during the last trading session, reaching $46.58. About 146,285 shares traded or 49.71% up from the average. Valero Energy Partners LP (NYSE:VLP) has risen 4.06% since January 17, 2017 and is uptrending. It has underperformed by 12.64% the S&P500.

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on February, 8. They expect $-0.46 earnings per share, down 17.95% or $0.07 from last year’s $-0.39 per share. After $-0.19 actual earnings per share reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts 142.11% negative EPS growth.

Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.52, from 1.3 in 2017Q2. It dropped, as 51 investors sold Seattle Genetics, Inc. shares while 74 reduced holdings. 29 funds opened positions while 69 raised stakes. 140.23 million shares or 2.00% more from 137.48 million shares in 2017Q2 were reported. Raymond James Assocs holds 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 6,950 shares. Creative Planning, Kansas-based fund reported 34,620 shares. The Nebraska-based Cwm Ltd Liability Com has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Hsbc Public Ltd Liability reported 0% stake. Great West Life Assurance Com Can holds 43,075 shares. First Manhattan, a New York-based fund reported 3,150 shares. Redmile Limited Co invested in 1.84 million shares or 4.95% of the stock. Tocqueville Asset Mngmt L P owns 0.02% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 27,190 shares. University Of Notre Dame Du Lac stated it has 55,319 shares or 0.84% of all its holdings. Metropolitan Life Insur Ny holds 7,215 shares or 0% of its portfolio. Macquarie Group Inc Ltd reported 95,917 shares stake. Sumitomo Mitsui Holdg Inc holds 280,692 shares or 0.02% of its portfolio. Primecap Management Ca owns 0.58% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 12.78 million shares. Raymond James Serv holds 4,654 shares or 0% of its portfolio. Jacobs Levy Equity Incorporated invested in 54,600 shares or 0.06% of the stock.

The stock decreased 2.69% or $1.41 during the last trading session, reaching $50.95. About 950,172 shares traded or 1.20% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since January 17, 2017 and is uptrending. It has outperformed by 58.98% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $7.33 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 11 Hold. Therefore 39% are positive. Seattle Genetics has $7500 highest and $4300 lowest target. $61.57’s average target is 20.84% above currents $50.95 stock price. Seattle Genetics had 56 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, August 16 by Oppenheimer. The firm earned “Neutral” rating on Friday, October 30 by Piper Jaffray. RBC Capital Markets maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Friday, October 27. RBC Capital Markets has “Buy” rating and $68.0 target. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 19 report. Cantor Fitzgerald maintained it with “Hold” rating and $4300 target in Monday, June 26 report. The stock has “Neutral” rating by JP Morgan on Monday, October 30. The firm has “Hold” rating by Oppenheimer given on Tuesday, October 10. The stock has “Hold” rating by Oppenheimer on Thursday, June 15. Cantor Fitzgerald downgraded the shares of SGEN in report on Wednesday, July 27 to “Hold” rating. Bank of America upgraded Seattle Genetics, Inc. (NASDAQ:SGEN) on Friday, October 27 to “Hold” rating.

Since August 7, 2017, it had 0 insider buys, and 17 selling transactions for $9.99 million activity. Another trade for 25,506 shares valued at $1.22 million was made by SIEGALL CLAY B on Monday, August 28. Another trade for 1,788 shares valued at $85,635 was made by Cline Darren S on Monday, August 28. SIMPSON TODD E sold $501,176 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Wednesday, September 6. The insider HIMES VAUGHN B sold 10,000 shares worth $532,190. 10,000 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $475,414 were sold by DRACHMAN JONATHAN G. 25,000 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $1.31 million were sold by DOBMEIER ERIC.

Investors sentiment increased to 0.89 in Q3 2017. Its up 0.17, from 0.72 in 2017Q2. It improved, as 10 investors sold VLP shares while 26 reduced holdings. 7 funds opened positions while 25 raised stakes. 20.12 million shares or 2.93% less from 20.72 million shares in 2017Q2 were reported. Citigroup Inc reported 67,790 shares or 0% of all its holdings. Commonwealth Of Pennsylvania School Empls Retrmt Systems has invested 0.05% in Valero Energy Partners LP (NYSE:VLP). Ohio-based Mai Mgmt has invested 0.4% in Valero Energy Partners LP (NYSE:VLP). Us Bank & Trust De owns 6,227 shares. Cadence Cap Management Limited Com has invested 0.26% in Valero Energy Partners LP (NYSE:VLP). Duff And Phelps Inv Mngmt holds 302,440 shares. Texas Yale Capital holds 0.05% or 14,300 shares in its portfolio. Macquarie Group Inc Limited accumulated 0% or 29,700 shares. Bb&T Corporation invested in 5,000 shares. Tortoise Advsr Ltd Liability Com stated it has 5.73 million shares or 1.64% of all its holdings. Dreman Value Management L L C holds 0.02% or 953 shares. Deutsche State Bank Ag stated it has 0.01% in Valero Energy Partners LP (NYSE:VLP). Susquehanna Interest Grp Ltd Liability Partnership has 12,226 shares for 0% of their portfolio. Nelson Van Denburg & Campbell Wealth Mgmt Gp Ltd reported 0% in Valero Energy Partners LP (NYSE:VLP). Ameriprise Fincl holds 34,144 shares.

Tortoise Capital Advisors Llc decreased Dominion Energy Midstrm Prtn (NYSE:DM) stake by 497,583 shares to 6.45M valued at $205.16M in 2017Q3. It also reduced Nabors Industries Ltd (NYSE:NBR) stake by 111,621 shares and now owns 102 shares. Williams Partners LP New (ACMP) was reduced too.

Among 13 analysts covering Valero Energy Partners LP (NYSE:VLP), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Valero Energy Partners LP had 35 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Thursday, June 22. The company was initiated on Monday, October 26 by Credit Suisse. The stock of Valero Energy Partners LP (NYSE:VLP) earned “Neutral” rating by Citigroup on Wednesday, October 18. The firm has “Buy” rating given on Friday, March 24 by Scotia Capital. The stock of Valero Energy Partners LP (NYSE:VLP) earned “Buy” rating by RBC Capital Markets on Monday, October 9. Jefferies maintained Valero Energy Partners LP (NYSE:VLP) on Monday, October 16 with “Buy” rating. The stock of Valero Energy Partners LP (NYSE:VLP) earned “Outperform” rating by Raymond James on Thursday, April 21. RBC Capital Markets maintained Valero Energy Partners LP (NYSE:VLP) rating on Tuesday, January 16. RBC Capital Markets has “Buy” rating and $63.0 target. On Friday, January 6 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. The stock of Valero Energy Partners LP (NYSE:VLP) earned “Buy” rating by Jefferies on Wednesday, August 23.